Growth Factors of Diabetic Neuropathy Market
Diabetic neuropathy, a debilitating complication of diabetes, results from prolonged elevated blood sugar levels causing nerve damage, predominantly in the legs and feet. Symptoms range from pain and numbness tsevere complications affecting the digestive system, urinary tract, and cardiovascular functions. The global diabetic neuropathy market, valued at USD 3.61 billion in 2018, is projected treach USD 11.98 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.0% during the forecast period.
Rising Prevalence of Diabetes: A Catalyst for Market Growth
The increasing prevalence of diabetes is a primary driver of the diabetic neuropathy market. According tthe World Health Organization, the number of individuals diagnosed with diabetes is expected trise from 285 million t438 million by 2030. This surge underscores the urgent need for effective management and treatment options for diabetic neuropathy, propelling market expansion.
Technological Advancements in Drug Delivery Systems
Innovations in drug delivery systems are significantly enhancing the treatment landscape for diabetic neuropathy. Manufacturers are developing advanced delivery methods, including transdermal patches, mouth sprays, and powders, timprove patient compliance and therapeutic outcomes. Notably, the introduction of needle-free injection technology (NFIT) addresses the discomfort associated with daily insulin injections, offering a less invasive alternative for patients.
Regional Market Insights
In 2018, North America dominated the global diabetic neuropathy market, accounting for 60.66% of the share. This dominance is attributed tthe high prevalence of diabetes, advanced healthcare infrastructure, and early adoption of innovative therapies in the region. Europe is anticipated tbe the second-largest market, driven by a growing geriatric population and increased healthcare expenditure. Conversely, the Asia-Pacific region is expected texhibit the highest CAGR during the forecast period, fueled by rising diabetes prevalence, increasing awareness of diabetes management, and supportive government initiatives.
Challenges and Restraints
Despite the promising growth trajectory, the diabetic neuropathy market faces challenges, including the high cost of treatment and the availability of alternative therapies. The emergence of non-pharmacological treatments, such as physical therapy and lifestyle modifications, offers patients additional options, potentially impacting the market share of pharmaceutical interventions. Moreover, stringent regulatory frameworks and delays in product approvals can hinder market growth.
Key Market Players and Strategic Developments
Leading pharmaceutical companies are actively investing in research and development tintroduce novel therapeutics for diabetic neuropathy. For instance, Novartis AG launched Tegerton (carbamazepine), an anti-convulsant medication aimed at reducing nerve impulses that cause pain in diabetic neuropathy patients. Such strategic initiatives are expected tenhance treatment efficacy and expand market reach.
Future Outlook
The diabetic neuropathy market is poised for substantial growth, driven by the escalating prevalence of diabetes and continuous advancements in treatment modalities. The focus on developing cost-effective and patient-friendly therapies is likely timprove patient adherence and outcomes. Additionally, increasing awareness and early diagnosis of diabetic neuropathy will play a crucial role in managing the condition effectively, thereby reducing the burden on healthcare systems globally.
In conclusion, the diabetic neuropathy market presents significant opportunities for growth, innovation, and improved patient care. Addressing the challenges through collaborative efforts between healthcare providers, researchers, and policymakers will be essential in combating this pervasive complication of diabetes.
ATTRIBUTE DETAILS
Study Period - 2015-2026
Base Year - 2018
Forecast Period - 2019-2026
Historical Period - 2015-2017
Unit - Value (USD billion)
Segmentation By Disease Type
- Peripheral
- Autonomic
- Proximal
- Focal
- Non-Steroidal Anti-Inflammatory Drugs
- Opioid
- Anti-Depressants
- Anti-Seizure
- Others
- Hospitals Pharmacies
- Retail Pharmacies & Stores
- Online Pharmacies
- North America (U.S. and Canada)
- Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
- Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia- Pacific)
- Latin America (Brazil, Mexico, and Rest of Latin America)
- Middle East & Africa (South Africa, GCC, and Rest of Middle East & Africa)
Please Note: It will take 5-6 business days to complete the report upon order confirmation.
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 4. Key Insights
- 4.1. Key Industry Developments Such as Mergers, Acquisitions, and Collaborations
- 4.2. New Product Launches
- 4.3. Prevalence of Diabetic Neuropathy
- 4.4. Pipeline Analysis
- 5. Global Diabetic Neuropathy Market Analysis, Insights and Forecast, 2015-2026
- 5.1. Key Findings / Summary
- 5.2. Market Analysis, Insights and Forecast – By Disease Type
- 5.2.1. Peripheral
- 5.2.2. Autonomic
- 5.2.3. Proximal
- 5.2.4. Focal
- 5.3. Market Analysis, Insights and Forecast – By Drug Class
- 5.3.1. Non-Steroidal Anti-Inflammatory Drugs
- 5.3.2. Opioid
- 5.3.3. Anti-Depressants
- 5.3.4. Anti-Seizure
- 5.3.5. Others
- 5.4. Market Analysis, Insights and Forecast – By Distribution Channel
- 5.4.1. Hospitals Pharmacies
- 5.4.2. Retail Pharmacies & Stores
- 5.4.3. Online Pharmacies
- 5.5. Market Analysis, Insights and Forecast – By Country
- 5.5.1. North America
- 5.5.2. Europe
- 5.5.3. Asia Pacific
- 5.5.4. Latin America
- 5.5.5. Middle East & Africa
- 6. North America Diabetic Neuropathy Market Analysis, Insights and Forecast, 2015-2026
- 6.1. Key Findings / Summary
- 6.2. Market Analysis – By Disease Type
- 6.2.1. Peripheral
- 6.2.2. Autonomic
- 6.2.3. Proximal
- 6.2.4. Focal
- 6.3. Market Analysis – By Drug Class
- 6.3.1. Non-Steroidal Anti-Inflammatory Drugs
- 6.3.2. Opioid
- 6.3.3. Anti-Depressants
- 6.3.4. Anti-Seizure
- 6.3.5. Others
- 6.4. Market Analysis – By Distribution Channel
- 6.4.1. Hospitals Pharmacies
- 6.4.2. Retail Pharmacies & Stores
- 6.4.3. Online Pharmacies
- 6.5. Market Analysis – By Country
- 6.5.1. U.S.
- 6.5.2. Canada
- 7. Europe Diabetic Neuropathy Market Analysis, Insights and Forecast, 2015-2026
- 7.1. Key Findings / Summary
- 7.2. Market Analysis – By Disease Type
- 7.2.1. Peripheral
- 7.2.2. Autonomic
- 7.2.3. Proximal
- 7.2.4. Focal
- 7.3. Market Analysis – By Drug Class
- 7.3.1. Non-Steroidal Anti-Inflammatory Drugs
- 7.3.2. Opioid
- 7.3.3. Anti-Depressants
- 7.3.4. Anti-Seizure
- 7.3.5. Others
- 7.4. Market Analysis – By Distribution Channel
- 7.4.1. Hospitals Pharmacies
- 7.4.2. Retail Pharmacies & Stores
- 7.4.3. Online Pharmacies
- 7.5. Market Analysis – By Country/ sub-region
- 7.5.1. U.K.
- 7.5.2. Germany
- 7.5.3. France
- 7.5.4. Spain
- 7.5.5. Italy
- 7.5.6. Scandinavia
- 7.5.7. Rest of Europe
- 8. Asia Pacific Diabetic Neuropathy Market Analysis, Insights and Forecast, 2015-2026
- 8.1. Key Findings / Summary
- 8.2. Market Analysis – By Disease Type
- 8.2.1. Peripheral
- 8.2.2. Autonomic
- 8.2.3. Proximal
- 8.2.4. Focal
- 8.3. Market Analysis – By Drug Class
- 8.3.1. Non-Steroidal Anti-Inflammatory Drugs
- 8.3.2. Opioid
- 8.3.3. Anti-Depressants
- 8.3.4. Anti-Seizure
- 8.3.5. Others
- 8.4. Market Analysis – By Distribution Channel
- 8.4.1. Hospitals Pharmacies
- 8.4.2. Retail Pharmacies & Stores
- 8.4.3. Online Pharmacies
- 8.5. Market Analysis – By Country/ sub-region
- 8.5.1. Japan
- 8.5.2. China
- 8.5.3. India
- 8.5.4. Australia
- 8.5.5. Southeast Asia
- 8.5.6. Rest of Asia Pacific
- 9. Latin America Diabetic Neuropathy Market Analysis, Insights and Forecast, 2015-2026
- 9.1. Key Findings / Summary
- 9.2. Market Analysis – By Disease Type
- 9.2.1. Peripheral
- 9.2.2. Autonomic
- 9.2.3. Proximal
- 9.2.4. Focal
- 9.3. Market Analysis – By Drug Class
- 9.3.1. Non-Steroidal Anti-Inflammatory Drugs
- 9.3.2. Opioid
- 9.3.3. Anti-Depressants
- 9.3.4. Anti-Seizure
- 9.3.5. Others
- 9.4. Market Analysis – By Distribution Channel
- 9.4.1. Hospitals Pharmacies
- 9.4.2. Retail Pharmacies & Stores
- 9.4.3. Online Pharmacies
- 9.5. Market Analysis – By Country/ sub-region
- 9.5.1. Brazil
- 9.5.2. Mexico
- 9.5.3. Rest of Latin America
- 10. Middle East & Africa Diabetic Neuropathy Market Analysis, Insights and Forecast, 2015-2026
- 10.1. Key Findings / Summary
- 10.2. Market Analysis – By Disease Type
- 10.2.1. Peripheral
- 10.2.2. Autonomic
- 10.2.3. Proximal
- 10.2.4. Focal
- 10.3. Market Analysis – By Drug Class
- 10.3.1. Non-Steroidal Anti-Inflammatory Drugs
- 10.3.2. Opioid
- 10.3.3. Anti-Depressants
- 10.3.4. Anti-Seizure
- 10.3.5. Others
- 10.4. Market Analysis – By Distribution Channel
- 10.4.1. Hospitals Pharmacies
- 10.4.2. Retail Pharmacies & Stores
- 10.4.3. Online Pharmacies
- 10.5. Market Analysis – By Country/ sub-region
- 10.5.1. GCC Countries
- 10.5.2. South Africa
- 10.5.3. Rest of Middle East & Africa
- 11. Competitive Analysis
- 11.1. Key Industry Developments
- 11.2. Global Market Share Analysis (2018)
- 11.3. Competition Dashboard
- 11.4. Comparative Analysis – Major Players
- 11.5. Company Profiles
- 11.5.1. Abbott
- 11.5.1.1. Overview,
- 11.5.1.2. Products & services,
- 11.5.1.3. SWOT analysis,
- 11.5.1.4. Recent developments,
- 11.5.1.5. strategies,
- 11.5.1.6. financials (based on availability)
- 11.5.2. Eli Lilly and Company
- 11.5.2.1. Overview,
- 11.5.2.2. Products & services,
- 11.5.2.3. SWOT analysis,
- 11.5.2.4. Recent developments,
- 11.5.2.5. strategies,
- 11.5.2.6. financials (based on availability)
- 11.5.3. Pfizer.Inc
- 11.5.3.1. Overview,
- 11.5.3.2. Products & services,
- 11.5.3.3. SWOT analysis,
- 11.5.3.4. Recent developments,
- 11.5.3.5. strategies,
- 11.5.3.6. financials (based on availability)
- 11.5.4. F. Hoffmann-La Roche Ltd
- 11.5.4.1. Overview,
- 11.5.4.2. Products & services,
- 11.5.4.3. SWOT analysis,
- 11.5.4.4. Recent developments,
- 11.5.4.5. strategies,
- 11.5.4.6. financials (based on availability)
- 11.5.5. GlaxoSmithKline plc.
- 11.5.5.1. Overview,
- 11.5.5.2. Products & services,
- 11.5.5.3. SWOT analysis,
- 11.5.5.4. Recent developments,
- 11.5.5.5. strategies,
- 11.5.5.6. financials (based on availability)
- 11.5.6. Janssen Pharmaceuticals, Inc.
- 11.5.6.1. Overview,
- 11.5.6.2. Products & services,
- 11.5.6.3. SWOT analysis,
- 11.5.6.4. Recent developments,
- 11.5.6.5. strategies,
- 11.5.6.6. financials (based on availability)
- 11.5.7. Lupin Pharmaceuticals, Inc.
- 11.5.7.1. Overview,
- 11.5.7.2. Products & services,
- 11.5.7.3. SWOT analysis,
- 11.5.7.4. Recent developments,
- 11.5.7.5. strategies,
- 11.5.7.6. financials (based on availability)
- 11.5.8. Astellas Pharma US, Inc.
- 11.5.8.1. Overview,
- 11.5.8.2. Products & services,
- 11.5.8.3. SWOT analysis,
- 11.5.8.4. Recent developments,
- 11.5.8.5. strategies,
- 11.5.8.6. financials (based on availability)
- 11.5.9. Other Prominent Players
- 11.5.9.1. Overview,
- 11.5.9.2. Products & services,
- 11.5.9.3. SWOT analysis,
- 11.5.9.4. Recent developments,
- 11.5.9.5. strategies,
- 11.5.9.6. financials (based on availability)
- 12. Strategic Recommendations
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook